Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the Securities and Exchange Commission (the "SEC") on October 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the SEC on October 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the SEC on October 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the SEC on October 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the SEC on October 30, 2026.


SCHEDULE 13G



 
Frazier Life Sciences X, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:11/09/2026
 
FHMLS X, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:11/09/2026
 
FHMLS X, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:11/09/2026
 
James N. Topper
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney
Date:11/09/2026
 
Patrick J. Heron
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney
Date:11/09/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement

ex-99-11092026_091150.htm

EXHIBIT 99.1


JOINT FILING AGREEMENT


Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Shares of Common Stock of Aspen Neuroscience, Inc.

 

Date:  November 9, 2026

FRAZIER LIFE SCIENCES X, L.P.

By: FHMLS X, L.P., its General Partner

By: FHMLS X, L.L.C., its General Partner


By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer



Date:  November 9, 2026

FHMLS X, L.P.

By: FHMLS X, L.L.C., its General Partner


By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer



Date:  November 9, 2026

FHMLS X, L.L.C.


By: /s/ Jennifer Martin

Jennifer Martin, Chief Financial Officer



Date:  November 9, 2026

By: *

James N. Topper



Date:  November 9, 2026

By: *

Patrick J. Heron



Date:  November 9, 2026

By: /s/ Jennifer Martin

Jennifer Martin, as Attorney-in-Fact


* This Joint Filing Agreement was executed by Jennifer Martin on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026.